PDL BioPharma Inc  

(Public, NASDAQ:PDLI)   Watch this stock  
Find more results for pdli
+0.15 (1.59%)
Jul 10 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 9.34 - 9.60
52 week 7.38 - 10.20
Open 9.35
Vol / Avg. 0.00/2.00M
Mkt cap 1.54B
P/E 5.38
Div/yield 0.15/6.26
EPS 1.78
Shares 160.59M
Beta 0.49
Inst. own 98%
Aug 4, 2014
Q2 2014 PDL BioPharma Earnings Release (Estimated) Add to calendar
Jun 26, 2014
PDL BioPharma Inc at Janney Investor 1x1 Day
Jun 25, 2014
PDL BioPharma Inc at JMP Securities Healthcare Conference
Jun 5, 2014
PDL BioPharma at Jefferies Global Healthcare Conference
May 28, 2014
PDL BioPharma Annual Shareholder Meeting
May 15, 2014
PDL BioPharma at Bank of America Merrill Lynch Health Care Conference
May 12, 2014
Q1 2014 PDL BioPharma Earnings Conference Call
May 12, 2014
Q1 2014 PDL BioPharma Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '14) 2013
Net profit margin 52.18% 59.72%
Operating margin 83.78% 92.01%
EBITD margin - 93.28%
Return on average assets 41.87% 64.21%
Return on average equity 185.19% 1166.18%
Employees 8 -
CDP Score - -


932 Southwood Blvd
United States - Map
+1-775-8328500 (Phone)
+1-775-8328501 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
Transcripts - SeekingAlpha


PDL BioPharma, Inc. (PDL) is a is a biotech company. PDL is engaged in the management of antibody humanization patents and royalty assets, which consist of its Queen et al. patents and license agreements with various biotechnology and pharmaceutical companies. The Company receives royalties based on sales of humanized antibody products marketed and may also receive royalty payments on additional humanized antibody products launched before final expiry in December 2014. It has entered into licensing agreements with numerous entities that are independently developing or have developed humanized antibodies under which it has licensed certain rights under its Queen et al. patents to make, use, sell, offer for sale and import humanized antibodies.

Officers and directors

John P. McLaughlin President, Chief Executive Officer, Director
Age: 62
Bio & Compensation  - Reuters
Peter S. Garcia Chief Financial Officer, Vice President
Age: 52
Bio & Compensation  - Reuters
David Montez CPA Chief Accounting Officer, Controller
Age: 40
Bio & Compensation  - Reuters
Christopher Lewis Stone J.D. Vice President, General Counsel, Secretary
Age: 49
Bio & Compensation  - Reuters
Danny Hart Deputy General Counsel, Assistant Secretary
Age: 38
Bio & Compensation  - Reuters
David W. Gryska Independent Director
Age: 58
Bio & Compensation  - Reuters
Jody S. Lindell Independent Director
Age: 62
Bio & Compensation  - Reuters
Paul W. Sandman Independent Director
Age: 66
Bio & Compensation  - Reuters
Harold E. Selick Ph.D. Independent Director
Age: 59
Bio & Compensation  - Reuters